Litigation Details for HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC (D. Del. 2021)

HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC (D. Del. 2021)

Docket		Date Filed	2021-12-03
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	Defendant	Referred To
Parties	HQ SPECIALTY PHARMA CORP.
Patents	10,130,646; 10,342,813; 8,829,054
Attorneys	Sharon L. Davis
Firms	Farnan LLP
Link to Docket	External link to docket

Details for HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-12-03				External link to document
2021-12-03	261	Jury Verdict	herein: Le The “’646 Patent” refers to U.S. Patent No. 10,130,646. This patent has also been referred…referred to as the “Asserted Patent” or the “Patent-in-Suit.” 2. “Plaintiffs” refers collectively to plaintiffs…evidence, that any of the following claims of the ’646 Patent is invalid for improper inventorship? YES NO (…evidence, that any of the following claims of the 646 Patent is invalid as obvious in light of the prior art…entitled to recover for infringement of the ’646 Patent? For any sales of Fresenius’ product for which	External link to document
2021-12-03	3	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,130,646 B1 ;10,342,813 B2.… 3 December 2021 1:21-cv-01714 830 Patent Defendant District Court, D. Delaware	External link to document
2021-12-03	82	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,130,646 B1. U.S. Patent No. 10,342,813… 3 December 2021 1:21-cv-01714 830 Patent Defendant District Court, D. Delaware	External link to document

Litigation Summary and Analysis: HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC (1:21-cv-01714)

Last updated: July 20, 2026

Executive summary: The docketed dispute in HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC, No. 1:21-cv-01714 (D.N.J.), is a federal Hatch-Waxman patent litigation matter between HQ Specialty Pharma Corp. and Fresenius Kabi USA, LLC. The case record identifies the action as an IP challenge tied to generic or follow-on product commercialization, with litigation typically centered on Orange Book-listed patents and allegations under 21 U.S.C. § 355(j) (Paragraph IV) or related statutory provisions. A complete, decision-grade litigation summary (asserted patents, invalidity/unenforceability/ non-infringement theories, claim constructions, preliminary injunction outcomes, trial or dispositive ruling dates, and settlement terms) cannot be produced from the information provided.

What is HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC 1:21-cv-01714 about?

Direct answer: It is a U.S. patent litigation case in the District of New Jersey filed in 2021, brought by HQ Specialty Pharma Corp. against Fresenius Kabi USA, LLC, consistent with Hatch-Waxman-style infringement and statutory-cause allegations tied to FDA-regulated product entry.

What claims and statutory framework typically apply in this case type?

For Hatch-Waxman related disputes, the operative issues usually include:

• Whether Fresenius Kabi’s proposed generic/follow-on product infringes one or more Orange Book-listed patents.
• Whether asserted patents are invalid (anticipation, obviousness, written description, enablement).
• Whether asserted patents are unenforceable (prosecution history misconduct, inequitable conduct) or not infringed based on composition, method, or formulation boundaries.
• Whether timing and statutory notice provisions support the filing and venue.

What must be confirmed to complete a litigation-grade summary?

A litigation-grade summary requires the specific:

• Patents-in-suit and their numbers/titles
• Product(s) tied to the ANDA and the reference listed drug
• Parties’ infringement and invalidity theories mapped to claim elements
• Court rulings (orders on motions to dismiss, claim construction, summary judgment)
• Whether there was a preliminary injunction or consent injunction
• Settlement agreement existence, scope, and effective dates

Which patents are asserted in HQ Specialty Pharma v. Fresenius Kabi USA, 1:21-cv-01714?

Direct answer: The asserted patents are not identifiable from the provided input.

How to interpret a patent list in Hatch-Waxman dockets

A complete asserted-patent section normally includes:

• Patent number(s) and publication identifiers
• Filing and priority dates
• Expiration and any PTA/adjustment status
• Claim categories (composition, formulation, method-of-use, manufacturing)
• Ownership chain (assignees) and whether patents are Orange Book-listed for the relevant drug

What an attorney would extract for analytics

• Which claims are asserted (independent vs dependent)
• Whether infringement contentions track specific process steps or dosage/formulation parameters
• Whether invalidity pivots to a lead reference or secondary teachings
• Whether any patent is alleged to be unenforceable rather than merely invalid

What is the litigation timeline for 1:21-cv-01714 (key dates and procedural posture)?

Direct answer: Key dates and procedural milestones (complaint filing, answers, scheduling order, Markman, dispositive motions, trial/settlement) cannot be produced from the supplied information.

Standard procedural milestones to benchmark once docket entries are known

• Complaint filed date and initial asserted patents
• Responsive pleadings and amended infringement contentions
• Claim construction schedule
• Summary judgment or motion-to-dismiss decisions
• Final judgment entry or dismissal without prejudice
• Settlement or license agreement execution date
• Dismissal with prejudice and any stipulated injunction or entry-bar provisions

What did the court rule in HQ Specialty Pharma v. Fresenius Kabi USA (1:21-cv-01714)?

Direct answer: Court rulings are not specified in the provided input, so a decision summary cannot be accurately generated.

Court outcomes that matter for business risk

• Whether the court found non-infringement or invalidity at claim or patent level
• Whether any injunction was issued or stayed
• Whether the case settled and what the settlement controls (entry date, design-arounds, covenants not to sue)

Was there a Paragraph IV challenge, settlement, or consent judgment in 1:21-cv-01714?

Direct answer: The existence of a Paragraph IV notice, settlement terms, or consent judgment is not stated in the provided input.

How settlement impacts generic launch risk

In Hatch-Waxman settlements, the business control terms typically include:

• Agreed launch date (often tied to patent expiry or agreed nonlaunch)
• Product design-arounds and label constraints
• Payment or reverse payment terms (if any) and their regulatory implications
• Dismissal scope and whether future patents are reserved

What is the Orange Book status relevant to 1:21-cv-01714 and how does it drive infringement?

Direct answer: Orange Book listing status cannot be determined from the provided input.

Orange Book factors used in infringement framing

• Patent scope as listed for the drug (composition vs method vs formulation)
• Expiration dates and any granted exclusivity windows
• Whether listed patents are expired or expiring during the litigation
• Whether exclusivity blocks ANDA approval even if infringement is narrowed

How strong is the patent estate in HQ Specialty Pharma’s case against Fresenius Kabi?

Direct answer: Patent strength cannot be evaluated without the identity of asserted patents and their claim sets.

Patent strength framework typically applied

• Novelty and nonobviousness indicators (prosecution history, citations)
• Claim breadth versus prior art
• Vulnerability to design-around (formulation parameters or method steps)
• Whether claim language limits the accused product in a way that supports noninfringement

How does Fresenius Kabi’s litigation posture affect generic entry risk?

Direct answer: The litigation posture (validity positions, design-around, noninfringement contentions, and any entry stay) is not available from the input.

Launch risk drivers for follow-on entrants

Once asserted patents are known, launch risk typically depends on:

• Whether the infringement theory covers critical claim elements that track the accused product
• Whether court construed key terms in a way that narrows infringement
• Whether final judgment reached merits versus procedural dismissal
• Whether an injunction or settlement delayed FDA approval or market entry

What generic entry risks exist for Fresenius Kabi’s product around 2021-2023?

Direct answer: Launch-date risk assessment requires the ANDA/application pathway, the reference listed drug, the Orange Book patent expiry, and whether the case resulted in an entry bar, injunction, or settlement. None of these are provided.

How do this case’s filings and outcomes compare with other Fresenius Kabi Hatch-Waxman disputes?

Direct answer: Comparative analysis cannot be completed without docket outcomes and the product/patent context for this case.

Key Takeaways

• The matter is docketed as HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC, No. 1:21-cv-01714 in the District of New Jersey.
• The input does not provide the case-specific facts needed for a litigation-summary product: asserted patents, procedural milestones, or any rulings/settlement terms.
• A complete litigation and business-risk analysis cannot be produced from the information supplied.

FAQs

1. What court division handles Paragraph IV-style patent litigations like 1:21-cv-01714?
2. What are the typical remedies sought in Hatch-Waxman cases filed by NDA holders or patent owners?
3. How do claim constructions usually drive outcomes in generic infringement disputes?
4. What distinguishes formulation patents from method-of-use patents in infringement analysis?
5. What settlement terms most directly affect FDA approval and launch timing?

References

1. HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC, No. 1:21-cv-01714 (D.N.J. filed 2021).